[go: up one dir, main page]

WO2001085959A3 - Regulation of human lysostaphin-like protease - Google Patents

Regulation of human lysostaphin-like protease Download PDF

Info

Publication number
WO2001085959A3
WO2001085959A3 PCT/EP2001/005347 EP0105347W WO0185959A3 WO 2001085959 A3 WO2001085959 A3 WO 2001085959A3 EP 0105347 W EP0105347 W EP 0105347W WO 0185959 A3 WO0185959 A3 WO 0185959A3
Authority
WO
WIPO (PCT)
Prior art keywords
lysostaphin
human
regulation
protease
reagents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/005347
Other languages
French (fr)
Other versions
WO2001085959A2 (en
Inventor
Shyam Ramakrishnan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to AU2001256350A priority Critical patent/AU2001256350A1/en
Publication of WO2001085959A2 publication Critical patent/WO2001085959A2/en
Publication of WO2001085959A3 publication Critical patent/WO2001085959A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reagents which regulate human lysostaphin-like protease activity and reagents which bind to human lysostaphin-like protease gene products can be used to regulate extracellular matrix degradation. Such regulation is particularly useful for treating metastasis of malignant cells, tumor angiogenesis, inflammation, cardiovascular disease, including hypertension, aneurysmal dilatation, and atherosclerosis, neurodegenerative diseases, and pathogenic infections.
PCT/EP2001/005347 2000-05-12 2001-05-10 Regulation of human lysostaphin-like protease Ceased WO2001085959A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001256350A AU2001256350A1 (en) 2000-05-12 2001-05-10 Regulation of human lysostaphin-like protease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20390800P 2000-05-12 2000-05-12
US60/203,908 2000-05-12

Publications (2)

Publication Number Publication Date
WO2001085959A2 WO2001085959A2 (en) 2001-11-15
WO2001085959A3 true WO2001085959A3 (en) 2002-06-20

Family

ID=22755795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/005347 Ceased WO2001085959A2 (en) 2000-05-12 2001-05-10 Regulation of human lysostaphin-like protease

Country Status (2)

Country Link
AU (1) AU2001256350A1 (en)
WO (1) WO2001085959A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4348194B2 (en) * 2001-12-21 2009-10-21 バイオシネクサス インコーポレーテッド A truncated lysostaphin molecule with enhanced staphylococcal lytic activity
CN1711101A (en) 2002-10-03 2005-12-21 Pr药品有限公司 Treatment of autism and similar disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 1 August 1998 (1998-08-01), DECKERT G ET AL: "The complete genome of the hyperthermophilic bacterium Aquifex olicus", XP002195534 *
DATABASE EMBL 29 March 1999 (1999-03-29), "National Cancer Institute/National Institute of Neurological Disorders and Stroke, Brain Tumor Genome Anatomy Project", XP002195533 *
NATURE, vol. 392, 1998, pages 353 - 358 *

Also Published As

Publication number Publication date
WO2001085959A2 (en) 2001-11-15
AU2001256350A1 (en) 2001-11-20

Similar Documents

Publication Publication Date Title
WO2001096538A3 (en) Regulation of human transmembrane serine protease
TR200101307T2 (en) Antranilic acid amides and their use as drugs.
PL351956A1 (en) Strain bacillus pumilus for control of plant diseases
WO2002008392A3 (en) Regulation of human matriptase-like serine protease
AU3987601A (en) Process for production of carotenoids, xanthophylls and apo-carotenoids utilizing eukaryotic microorganisms
AU2672099A (en) Compositions and methods for wound healing
WO2001085959A3 (en) Regulation of human lysostaphin-like protease
WO2001096378A3 (en) Human epithin-like serine protease
SE0000304D0 (en) Heat treatment of cereals
BR9811748A (en) Microbial genes for secreted ß-glucuronides, gene products and their uses
WO2001098340A3 (en) Regulation of human mast cell protease 6-like enzyme
AU2826801A (en) Surface modified supporting materials for binding biological materials, method for the production and use thereof
WO2001072973A3 (en) Regulation of human heparanase-like enzyme
WO2001098466A3 (en) Regulation of human prostasin-like serine protease
WO2001062941A3 (en) Regulation of human gelatinase b-like enzyme 2
WO2001079466A3 (en) Regulation of human epithin-like serine protease
WO2001098467A3 (en) Regulation of human prostasin-like serine protease
WO2002000702A3 (en) Regulation of human epidermis-specific serine protease
WO2002024886A3 (en) Regulation of human serine protease
WO2002012461A3 (en) Regulation of human membrane-type serine protease
AU2002251788A1 (en) Novel compounds and uses thereof
WO2002026957A3 (en) Regulation of a human serine protease
EP1085093A3 (en) Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof
WO2004000999A3 (en) Identification of a receptor controlling migration and metastasis of skin cancer cells
AU2001264245A1 (en) Novel enzyme gene and its expression product

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP